Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1821736 in Advanced Solid Tumors
NCT05839600Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 1, open-label trial of BI 1821736 in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Jun 2023; status: terminated.
02
Drugs
BI 1821736
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05839600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839600.